Physician profile
Mark James Hontas
NPI 1417042706
$2,299.78
in general payments reported to CMS, 2019-2025
14 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $258 · 2021: $347 · 2022: $912 · 2023: $26.76 · 2024: $421 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $1,758.55 | 2020-2025 | Na, Va-Lcp, Attune |
| Stryker Corporation | $167.43 | 2019-2024 | Triathlon, Mako, Gamma |
| Ferring Pharmaceuticals INC. | $113.70 | 2019-2025 | Euflexxa |
| Globus Medical, INC. | $50.11 | 2024 | Mini Fragment System |
| Heron Therapeutics, INC. | $34.11 | 2024 | Zynrelef |
| Sanofi-Aventis U.S. LLC | $28.57 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $24.30 | 2022 | |
| Davol INC. | $22.42 | 2024 | Channel Drain |
| Innovation Technologies INC | $20.85 | 2024 | Irrisept |
| Vertex Pharmaceuticals Incorporated | $17.96 | 2024 | |
| Pacira Therapeutics, INC. | $17.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2022 | |
| Ethicon US, LLC | $15.58 | 2020 | |
| Smith+Nephew, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark James Hontas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.